The challenges of vaccine development are not limited to identification of suitable antigens, adjuvants and delivery methods, but include regulatory, technical and manufacturing hurdles in translating a vaccine candidate to the clinic.
McLaren's Martin Whitmarsh wants a solution which "may or may not include a budget cap, but which ideally would not encompass a two-tier regulatory framework".